proefschrift ondersteuning

De FNT ondersteunt jaarlijks financieel een aantal proefschriften. U kunt hiervoor een aanvraag indienen die o.a. een inhoudsopgave bevat van uw proefschrift.
De aanvraag, gericht aan het bestuur van de FNT, kunt u sturen naar fnt@fnt.nl

Klik hier voor de procedure 'financiële ondersteuning en aanschaf proefschriften.

Gehonoreerd in 2020:

  • B. Nemeth: Venous thrombosis following lower-leg cast immobilization and knee arthroscopy: From a population-based approach to individualized therapy.
  • M. Jacobs: Anticoagulation in Atrial Fibrillation. Consideration for treatment and health economic aspects.

Gehonoreerd in 2019:

  • L.J.J. Scheres: Sex, Hormones & Clots: sex-specific mechanisms and woman-specific models for risk assessment & management in thrombosis.
  • L.M. van der Pol; Improving the efficiency of the diagnostic management of pulmonary thromboembolism.
  • Y.M. Ende-Verhaar; Prediction of long-term complications of venous thromboembolism.
  • A.R. Dreijer; Antithrombotic stewardship.
  • N. Kraaijpoel; Cancer-associated venous thromboembolism; advances in diagnosis and treatment.
  • V. ten Cate; Evolving Startegies in the Prevention and Treatment of Venous Thromboembolism.

Gehonoreerd in 2018:

  • C.E.A. Dronkers: Deep veinThrombosis, Diagnostic and prognostic challenges. 
  • H. Maagdenberg: Precision anticoagulation with vitamin K antagonists in children.
  • N. Croles: The role of antithrombotin in venous and arterial thrombosis.
  • S.J. van der Wall: Venous and arterial thrombotic complications - solutions in clinical practice.
  • M. Brekelmans: Treatment of venous thromboembolism: focus on patient characteristics and bleeding complications.

Genonoreerd in 2017:

  • M. Vries; Assessment of Bleeding Risk. Preoperatively and in the context of antiplatelet therapy.
  • J. Biedermann; Optimization of monitoring and management of anticoagulant therapy.
  • N. van Es; Cancer and thrombosis; improvements in strategies for prediction, diagnosis and treatment.
  • R. Folkeringa; Target Specific AF management.
  • N. van Rein; Risk and prevention of bleeding during anticoagulant treatment.